The global Crohn’s disease (CD) market value is forecast to show modest growth, climbing from $3.2 billion in 2012 to $4.2 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 2.8%, according to a new report from research and consulting firm GlobalData.
The company’s latest report states that out of the 10 major markets (the U.S., France, Germany, Italy, Spain, the UK, Japan, Canada, China and India), the U.S. will continue to hold the largest CD market share by 2022, with 68%, followed by Canada and Japan with 8% and 7%, respectively.
One of the main drivers behind the CD treatment market is the anticipated launch of the first non-anti-tumor necrosis factor (TNF) biologics, such as Takeda’s Entyvio (vedolizumab) and Johnson & Johnson’s (J&J’s) Stelara (ustekinumab).
Tina Healy, GlobalData’s Director for Immunology, says that J&J is best positioned to remain a key contender over the forecast period. Although patent expiry looms for its leading brand Remicade (infliximab), Stelara is anticipated to launch in 2015. AbbVie’s Humira (adalimumab), however, is expected to lose almost half of its 2012 market value by 2022, according to the report.